Thomas L Holland
Overview
Explore the profile of Thomas L Holland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
3676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mourad A, Grandits G, Siegel L, Engen N, Barkauskas C, Eriobu N, et al.
Clin Microbiol Infect
. 2025 Feb;
PMID: 39922466
Objectives: Passive immunotherapy, including monoclonal antibodies and neutralizing proteins, was used for the treatment of patients with COVID-19 during the pandemic. Accelerating COVID-19 Therapeutic Interventions and Vaccines-Therapeutics for Inpatients with...
2.
Guerra-de-Blas P, Marines-Price R, Milman O, Deal D, Marchand J, Linton J, et al.
J Clin Transl Sci
. 2024 Nov;
8(1):e157.
PMID: 39610837
The emergence of the COVID-19 pandemic required an immediate global clinical research response. The ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines)-3 trials and the ACTIV-associated Outpatient Treatment with Anti-Coronavirus Immunoglobulin...
3.
4.
Mourad A, Nwafo N, Skalla L, Holland T, Jenkins T
Clin Infect Dis
. 2024 Sep;
80(1):29-36.
PMID: 39290168
Background: We conducted a systematic review of randomized, controlled trials (RCTs) to generate more precise estimates of the efficacy and safety of oral versus intravenous antibiotic therapy for Staphylococcus aureus...
5.
Madut D, Chemaly R, Dadwal S, Hill J, Lee Y, Haidar G, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae425.
PMID: 39091643
Background: Plasma microbial cell-free DNA (mcfDNA) sequencing can establish the etiology of multiple infectious syndromes by identifying microbial DNA in plasma. However, data are needed to define the clinical scenarios...
6.
Sutton A, Lupu D, Bergin S, Holland T, McAdams S, Dadwal S, et al.
Pharmacoeconomics
. 2024 Jul;
42(9):1029-1045.
PMID: 38955978
Introduction: Immunocompromised host pneumonia (ICHP) is an important cause of morbidity and mortality, yet usual care (UC) diagnostic tests often fail to identify an infectious etiology. A US-based, multicenter study...
7.
Mourad A, Niehaus E, Fowler Jr V, Holland T
Clin Microbiol Infect
. 2024 Jun;
30(9):1199-1201.
PMID: 38851425
No abstract available.
8.
Mourad A, Smith A, Troy J, Holland T, Wrenn R, Turner N
J Antimicrob Chemother
. 2024 May;
79(6):1456-1461.
PMID: 38708907
Background: A small proportion of Escherichia coli and Klebsiella pneumoniae demonstrate in vitro non-susceptibility to piperacillin/tazobactam but retain susceptibility to ceftriaxone. Uncertainty remains regarding how best to treat these isolates....
9.
Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg S, et al.
Clin Infect Dis
. 2024 Mar;
79(1):60-69.
PMID: 38527855
Background: Desirability of outcome ranking (DOOR) is an innovative approach to clinical trial design and analysis that uses an ordinal ranking system to incorporate the overall risks and benefits of...
10.
Hillenbrand M, Mourad A, Holland T, Turner N
Clin Microbiol Infect
. 2024 Feb;
30(6):703-706.
PMID: 38341142
No abstract available.